Targeting OCT3 attenuates doxorubicin-induced cardiac injury
- 25 January 2021
- journal article
- research article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences of the United States of America
- Vol. 118 (5)
- https://doi.org/10.1073/pnas.2020168118
Abstract
Doxorubicin is a commonly used anticancer agent that can cause debilitating and irreversible cardiac injury. The initiating mechanisms contributing to this side effect remain unknown, and current preventative strategies offer only modest protection. Using stem-cell–derived cardiomyocytes from patients receiving doxorubicin, we probed the transcriptomic landscape of solute carriers and identified organic cation transporter 3 (OCT3) (SLC22A3) as a critical transporter regulating the cardiac accumulation of doxorubicin. Functional validation studies in heterologous overexpression models confirmed that doxorubicin is transported into cardiomyocytes by OCT3 and that deficiency of OCT3 protected mice from acute and chronic doxorubicin-related changes in cardiovascular function and genetic pathways associated with cardiac damage. To provide proof-of-principle and demonstrate translational relevance of this transport mechanism, we identified several pharmacological inhibitors of OCT3, including nilotinib, and found that pharmacological targeting of OCT3 can also preserve cardiovascular function following treatment with doxorubicin without affecting its plasma levels or antitumor effects in multiple models of leukemia and breast cancer. Finally, we identified a previously unrecognized, OCT3-dependent pathway of doxorubicin-induced cardiotoxicity that results in a downstream signaling cascade involving the calcium-binding proteins S100A8 and S100A9. These collective findings not only shed light on the etiology of doxorubicin-induced cardiotoxicity, but also are of potential translational relevance and provide a rationale for the implementation of a targeted intervention strategy to prevent this debilitating side effect.Funding Information
- HHS | NIH | National Cancer Institute (R01CA215802)
- HHS | NIH | National Cancer Institute (R01CA187176)
- HHS | NIH | National Cancer Institute (R01CA238946)
- HHS | NIH | National Cancer Institute (R50CA211524)
- HHS | NIH | National Institute of General Medical Sciences (R01GM066233)
This publication has 57 references indexed in Scilit:
- The Cancer Genome Atlas Pan-Cancer analysis projectNature Genetics, 2013
- Selective Regulation of Cardiac Organic Cation Transporter Novel Type 2 (OCTN2) in Dilated CardiomyopathyThe American Journal of Pathology, 2011
- Interactions of Tyrosine Kinase Inhibitors with Organic Cation Transporters and Multidrug and Toxic Compound Extrusion ProteinsMolecular Cancer Therapeutics, 2011
- The Organic Cation Transporter, OCTN1, Expressed in the Human Heart, Potentiates Antagonism of the HERG Potassium ChannelJournal of Cardiovascular Pharmacology, 2009
- Profiling SLCO and SLC22 genes in the NCI-60 cancer cell lines to identify drug uptake transportersMolecular Cancer Therapeutics, 2008
- Toll‐like receptor‐4 deficiency attenuates doxorubicin‐induced cardiomyopathy in miceEuropean Journal of Heart Failure, 2008
- Expression of Organic Cation Transporter SLC22A16 in Human Epithelial Ovarian CancerInternational Journal of Gynecological Pathology, 2007
- Local inhibition of organic cation transporters increases extracellular serotonin in the medial hypothalamusBrain Research, 2005
- Characterization of the organic cation transporter SLC22A16: A doxorubicin importerBiochemical and Biophysical Research Communications, 2005
- A Fickian diffusion transport process with features of transport catalysis. Doxorubicin transport in human red blood cells.The Journal of general physiology, 1981